Uptake of clinical genetic testing for ovarian cancer in Ontario: A population-based study

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 68-72

  Metcalfe, Kelly A ^a,b   Fan, Isabel ^c   McLaughlin, John ^c   Risch, Harvey A ^d   Rosen, Barry ^e   Murphy, Joan ^e   Bradley, Linda ^c   Armel, Susan ^e   Sun, Ping ^b   Narod, Steven A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c Mount Sinai/Princess Margaret Hospitals   (Canada)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

BRCA1; BRCA2; Genetic testing; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANADA; CANCER DIAGNOSIS; CANCER GENETICS; CANCER REGISTRY; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PUBLIC HEALTH; RISK FACTOR; TIME SERIES ANALYSIS;

ADULT; AGED; DNA, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; ONTARIO; OVARIAN NEOPLASMS; YOUNG ADULT;

EID: 57649109447     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.10.007     Document Type: Article

References (20)

1. Narod S., Ford D., Devilee P., Barkardottir R.B., Eyfjord J., Lenoir G., et al. Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 57 4 (1995) 957-958 [Oct]
2. Moslehi R., Chu W., Karlan B., Fishman D., Risch H., Fields A., et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am. J. Hum. Genet. 66 4 (2000) 1259-1272 [Apr]
3. Modan B., Hartge P., Hirsh-Yechezkel G., Chetrit A., Lubin F., Beller U., et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345 4 (2001) 235-240 [Jul 26]
4. Tonin P.N., Mes-Masson A.M., Futreal P.A., Morgan K., Mahon M., Foulkes W.D., et al. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am. J. Hum. Genet. 63 5 (1998) 1341-1351 [Nov]
5. Kuperstein G., Foulkes W.D., Ghadirian P., Hakimi J., and Narod S.A. A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes. Clin. Genet. 57 3 (2000) 213-220 [Mar]
6. Puget N., Sinilnikova O.M., Stoppa-Lyonnet D., Audoynaud C., Pages S., Lynch H.T., et al. An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation?. Am. J. Hum. Genet. 64 1 (1999) 300-302 [Jan]
7. Kuperstein G., Jack E., and Narod S.A. A fluorescent multiplex-DGGE screening test for mutations in the BRCA1 gene. Genet. Test. 10 1 (2006) 1-7 [Spring]
8. Gross E., Arnold N., Pfeifer K., Bandick K., and Kiechle M. Identification of specific BRCA1 and BRCA2 variants by DHPLC. Hum. Mutat. 16 4 (2000) 345-353 [Oct]
9. Peelen T., van Vliet M., Bosch A., Bignell G., Vasen H.F., Klijn J.G., et al. Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. Br. J. Cancer 82 1 (2000) 151-156 [Jan]
10. Risch H.A., McLaughlin J.R., Cole D.E., Rosen B., Bradley L., Fan I., et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl. Cancer Inst. 98 23 (2006) 1694-1706 [Dec 6]
11. Malone K.E., Daling J.R., Doody D.R., Hsu L., Bernstein L., Coates R.J., et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 66 16 (2006) 8297-8308 [Aug 15]
12. Halbert C.H., Kessler L., Stopfer J.E., Domchek S., and Wileyto E.P. Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer. Genet. Med. 8 9 (2006) 576-582 [Sep]
13. Armstrong K., Micco E., Carney A., Stopfer J., and Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA 293 14 (2005) 1729-1736 [Apr 13]
14. Susswein L.R., Skrzynia C., Lange L.A., Booker J.K., Graham III M.L., and Evans J.P. Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer. J. Clin. Oncol. 26 1 (2008) 32-36 [Jan 1]
15. Biesecker B.B., Ishibe N., Hadley D.W., Giambarresi T.R., Kase R.G., Lerman C., et al. Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. Am. J. Med. Genet. 93 4 (2000) 257-263 [Aug 14]
16. Brooks L., Lennard F., Shenton A., Lalloo F., Ambus I., Ardern-Jones A., et al. BRCA1/2 predictive testing: a study of uptake in two centres. Eur. J. Hum. Genet. 12 8 (2004) 654-662 [Aug]
17. Julian-Reynier C., Sobol H., Sevilla C., Nogues C., and Bourret P. Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network. Psychooncology 9 6 (2000) 504-510 [Nov-Dec]
18. Lerman C., Narod S., Schulman K., Hughes C., Gomez-Caminero A., Bonney G., et al. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA 275 24 (1996) 1885-1892
19. Armstrong K., Calzone K., Stopfer J., Fitzgerald G., Coyne J., and Weber B. Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol., Biomarkers Prev. 9 11 (2000) 1251-1254 [Nov]
20. Lee S.C., Bernhardt B.A., and Helzlsouer K.J. Utilization of BRCA1/2 genetic testing in the clinical setting: report from a single institution. Cancer 94 6 (2002) 1876-1885 [Mar 15]